These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31751857)

  • 1. Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod.
    Feige J; Schernthaner C; Wipfler P; Sellner J
    Mult Scler Relat Disord; 2020 Feb; 38():101515. PubMed ID: 31751857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vagomimetic effects of fingolimod: physiology and clinical implications.
    Vanoli E; Pentimalli F; Botto G
    CNS Neurosci Ther; 2014 Jun; 20(6):496-502. PubMed ID: 24836740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic.
    Brown B; Weiss JL; Kolodny S; Meng X; Williams IM; Osborne JA
    BMC Neurol; 2019 Nov; 19(1):287. PubMed ID: 31729968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports.
    Kum YE; Pamukçu Ö; Canpolat M
    Cardiol Young; 2023 Nov; 33(11):2384-2386. PubMed ID: 37170775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.
    Limmroth V; Ziemssen T; Lang M; Richter S; Wagner B; Haas J; Schmidt S; Gerbershagen K; Lassek C; Klotz L; Hoffmann O; Albert C; Schuh K; Baier-Ebert M; Wendt G; Schieb H; Hoyer S; Dechend R; Haverkamp W
    BMC Neurol; 2017 Jan; 17(1):11. PubMed ID: 28100182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.
    Akbulak RÖ; Rosenkranz SC; Schaeffer BN; Pinnschmidt HO; Willems S; Heesen C; Hoffmann BA
    Mult Scler Relat Disord; 2018 Jan; 19():44-49. PubMed ID: 29127856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolimod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
    Yagi Y; Nakamura Y; Kitahara K; Harada T; Kato K; Ninomiya T; Cao X; Ohara H; Izumi-Nakaseko H; Suzuki K; Ando K; Sugiyama A
    Toxicol Appl Pharmacol; 2014 Nov; 281(1):39-47. PubMed ID: 25223691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod.
    Vanoli E; Montano N; De Angelis G; Badilini F; Mirabella M; Bonavita S; Patti F; Bianco A; Sparaco M; Chisari C; Laroni A; Frigerio F; Bartezaghi M; Rossi S; Turrini R; Mancardi G
    J Neurol Sci; 2019 Oct; 405():116423. PubMed ID: 31520869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
    Chinea Martinez AR; Correale J; Coyle PK; Meng X; Tenenbaum N
    Adv Ther; 2014 Oct; 31(10):1072-81. PubMed ID: 25245812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early safety and efficacy of fingolimod treatment in Denmark.
    Voldsgaard A; Koch-Henriksen N; Magyari M; Sellebjerg F; Sørensen PS; Oturai AB
    Acta Neurol Scand; 2017 Jan; 135(1):129-133. PubMed ID: 27910101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.
    DiMarco JP; O'Connor P; Cohen JA; Reder AT; Zhang-Auberson L; Tang D; Collins W; Kappos L
    Mult Scler Relat Disord; 2014 Sep; 3(5):629-38. PubMed ID: 26265275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of sphingosine receptors influences circadian pattern of cardiac autonomic regulation.
    Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JE
    Physiol Rep; 2016 Sep; 4(17):. PubMed ID: 27624686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?
    Orrico M; Nozzolillo A; Gelibter S; Sangalli F; Preziosa P; Filippi M; Moiola L
    J Neurol; 2021 Nov; 268(11):3975-3979. PubMed ID: 33852086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Hughes B; Cascione M; Freedman MS; Agius M; Kantor D; Gudesblatt M; Goldstick LP; Agashivala N; Schofield L; McCague K; Hashmonay R; Barbato L;
    Mult Scler Relat Disord; 2014 Sep; 3(5):620-8. PubMed ID: 26265274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ventricular tachycardia after initiation of fingolimod.
    Elounais F; Aburahma A; Alkotob ML; Al Hadidi S
    BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28954755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.
    Bermel RA; Hashmonay R; Meng X; Randhawa S; von Rosenstiel P; Sfikas N; Kantor D
    Mult Scler Relat Disord; 2015 May; 4(3):273-80. PubMed ID: 26008945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryptococcal meningoencephalitis in an IgG
    Wienemann T; Müller AK; MacKenzie C; Bielor C; Weyers V; Aktas O; Hartung HP; Kremer D
    BMC Neurol; 2020 Apr; 20(1):158. PubMed ID: 32340606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobitz type I and II atrioventricular blocks during fingolimod therapy.
    Saccà F; Puorro G; Marsili A; Pane C; Russo CV; Lanzillo R; de Rosa A; Cittadini A; De Angelis G; Brescia Morra V
    Neurol Sci; 2016 Sep; 37(9):1557-9. PubMed ID: 27225279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.